An oral pill was supposed to be the convenient psoriasis option that quietly trades away potency. Two years in, Johnson & Johnson's peptide gained skin clearance instead of losing it, and it held at the body sites where psoriasis is hardest to treat.
The drug is icotrokinra, sold as Icotyde, a once-daily tablet that is a peptide rather than the usual injected antibody or small molecule. The two-year data from the Phase 3 ICONIC-TOTAL study landed as a late-breaking presentation at the European Academy of Dermatology and Venereology congress in Vienna, and Johnson & Johnson announced it on Friday, October 2.
What the trial measured
ICONIC-TOTAL enrolled 311 people aged 12 and up whose psoriasis sits on the scalp, the genitals, or the hands and feet. Dermatologists call those sites difficult to treat. Topical creams are awkward or unsafe to use there, and clearance at those sites tends to lag the rest of the body. Of the 311 patients, 208 started on icotrokinra. The other 103 started on placebo, then switched to the drug at week 16.
Doctors scored patients on a five-point scale where 0 means clear skin and 1 means almost clear. The share of treated patients hitting clear or almost clear climbed over time rather than fading. It was 57 percent at week 16, 67 percent at week 24, and 70 percent at week 112, which is a little past two years.
The site-by-site numbers are the point of the study. By week 112, among patients with disease at each site, 60 percent reached completely clear scalp skin, 89 percent completely clear genital skin, and 63 percent completely clear hands or feet. Nail psoriasis, which is slow and stubborn, improved by an average of 71 percent on a standard nail-severity scale. Johnson & Johnson reported no new safety signals through the two years, and missing data after week 52 was filled in statistically rather than measured.
Why an oral peptide here is the story
Psoriasis is driven in part by a signaling protein called interleukin-23, which acts like a switch that keeps immune cells inflamed. The strongest psoriasis drugs are antibodies that block that pathway, and they work well, but they are injections. Icotrokinra blocks the same pathway at the IL-23 receptor, and it does it as a pill.
That combination is the hard part. A peptide is a short chain of amino acids, the same chemistry as a protein. The gut is built to chop those up before they reach the bloodstream, so most peptide drugs are injected. Getting one to survive the stomach, cross into circulation, and then hold a chronic disease in check for two years is a delivery problem the field has worked at for a decade. The durability here rose rather than drifted down. That is the evidence an oral peptide can carry a chronic indication the way an injected biologic does.
The convenience is not a footnote at these sites. Picture a patient with genital or scalp psoriasis taking a daily tablet instead of a needle, and seeing roughly nine in ten genital cases clear. That is the case for the whole oral-peptide bet.
The platform thread
Icotrokinra is co-developed by Johnson & Johnson and Protagonist Therapeutics. It is one of the few fully peptidic oral drugs to reach a chronic indication at scale. peptidemodel treats oral peptides as a drug class worth tracking, not a curiosity, and the psoriasis pathway shows up in that corpus from the other direction too. In August the section covered a synthetic peptide called WMX-8 ↗. That one blocked a neighboring psoriasis receptor, interleukin-17, but only in cultured cells. The gap between the two pieces is the whole climb. One peptide matched an antibody in a dish. The other held clear skin in patients for two years.